Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Summary

This study encompasses multicenter open-label, phase II trials. Patients will be dispatched into 2 cohorts: * Cohort A: Patients naïve from systemic treatment will be randomized according to two treatment modalities: atezolizumab + tiragolumab (arm A1) versus atezolizumab monotherapy (arm A2). 43 patients are to be included in each arm. * Cohort B: Patients with previous exposure to ICI will be treated with the combination of atezolizumab and tiragolumab. 29 patients are to be included in this cohort.

Timeline

Start

2025-01-30

Primary completion

2025-09-15

Completion

2025-09-15

Drugs

Indications